{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:46:37Z","timestamp":1762883197248,"version":"3.45.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-19423-7","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:42:05Z","timestamp":1762882925000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gross tumor assessment is not a reliable measure of the efficacy of chemo-preventive agents for breast cancer in preclinical mouse models"],"prefix":"10.1038","volume":"15","author":[{"given":"Anjana","family":"Bhardwaj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew D.","family":"Embury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janvi","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raniv D.","family":"Rojo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constance T.","family":"Albarracin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Bedrosian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"19423_CR1","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.exger.2005.07.007","volume":"40","author":"VN Anisimov","year":"2005","unstructured":"Anisimov, V. N. et al. Effect of Metformin on life span and on the development of spontaneous mammary tumors in HER-2\/neu Transgenic mice. Exp. Gerontol. 40, 685\u2013693. https:\/\/doi.org\/10.1016\/j.exger.2005.07.007 (2005).","journal-title":"Exp. Gerontol."},{"key":"19423_CR2","doi-asserted-by":"publisher","first-page":"188","DOI":"10.4161\/cc.9.1.10407","volume":"9","author":"VN Anisimov","year":"2010","unstructured":"Anisimov, V. N. et al. Metformin extends life span of HER-2\/neu Transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell. Cycle. 9, 188\u2013197. https:\/\/doi.org\/10.4161\/cc.9.1.10407 (2010).","journal-title":"Cell. Cycle"},{"key":"19423_CR3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.4149\/neo_2009_03_269","volume":"56","author":"B Bojkova","year":"2009","unstructured":"Bojkova, B. et al. Metformin in chemically-induced mammary carcinogenesis in rats. Neoplasma 56, 269\u2013274. https:\/\/doi.org\/10.4149\/neo_2009_03_269 (2009).","journal-title":"Neoplasma"},{"key":"19423_CR4","doi-asserted-by":"publisher","first-page":"5902","DOI":"10.1158\/1078-0432.CCR-06-1119","volume":"12","author":"K Liby","year":"2006","unstructured":"Liby, K. et al. The combination of the rexinoid, LG100268, and a selective Estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an Estrogen receptor-negative model of breast cancer. Clin. Cancer Res. 12, 5902\u20135909. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1119 (2006).","journal-title":"Clin. Cancer Res."},{"key":"19423_CR5","doi-asserted-by":"publisher","first-page":"4556","DOI":"10.1158\/1078-0432.CCR-08-0040","volume":"14","author":"K Liby","year":"2008","unstructured":"Liby, K. et al. Prevention and treatment of experimental Estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl ester and the rexinoid LG100268. Clin. Cancer Res. 14, 4556\u20134563. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0040 (2008).","journal-title":"Clin. Cancer Res."},{"key":"19423_CR6","first-page":"1339","volume":"39","author":"RC Moon","year":"1979","unstructured":"Moon, R. C. et al. N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res. 39, 1339\u20131346 (1979).","journal-title":"Cancer Res."},{"key":"19423_CR7","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1126\/science.1130471","volume":"314","author":"AJ Poole","year":"2006","unstructured":"Poole, A. J. et al. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314, 1467\u20131470. https:\/\/doi.org\/10.1126\/science.1130471 (2006).","journal-title":"Science"},{"key":"19423_CR8","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1158\/1940-6207.CAPR-14-0110","volume":"8","author":"L Rossdeutscher","year":"2015","unstructured":"Rossdeutscher, L. et al. Chemoprevention activity of 25-hydroxyvitamin D in the MMTV-PyMT mouse model of breast cancer. Cancer Prev. Res. (Phila). 8, 120\u2013128. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-14-0110 (2015).","journal-title":"Cancer Prev. Res. (Phila)"},{"key":"19423_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/jnci\/djn436","volume":"101","author":"TE Strecker","year":"2009","unstructured":"Strecker, T. E. et al. Effect of lapatinib on the development of Estrogen receptor-negative mammary tumors in mice. J. Natl. Cancer Inst. 101, 107\u2013113. https:\/\/doi.org\/10.1093\/jnci\/djn436 (2009).","journal-title":"J. Natl. Cancer Inst."},{"key":"19423_CR10","first-page":"3270","volume":"8","author":"N Suh","year":"2002","unstructured":"Suh, N. et al. Prevention and treatment of experimental breast cancer with the combination of a new selective Estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268. Clin. Cancer Res. 8, 3270\u20133275 (2002).","journal-title":"Clin. Cancer Res."},{"key":"19423_CR11","doi-asserted-by":"publisher","first-page":"R586","DOI":"10.1186\/bcr914","volume":"6","author":"E Unni","year":"2004","unstructured":"Unni, E., Kittrell, F. S., Singh, U. & Sinha, R. Osteopontin is a potential target gene in mouse mammary cancer chemoprevention by Se-methylselenocysteine. Breast Cancer Res. 6, R586\u2013592. https:\/\/doi.org\/10.1186\/bcr914 (2004).","journal-title":"Breast Cancer Res."},{"key":"19423_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1023\/a:1006490000659","volume":"65","author":"DW Visscher","year":"2001","unstructured":"Visscher, D. W., Nanjia-Makker, P., Heppner, G. & Shekhar, P. V. Tamoxifen suppresses histologic progression to atypia and DCIS in MCFIOAT xenografts, a model of early human breast cancer. Breast Cancer Res. Treat. 65, 41\u201347. https:\/\/doi.org\/10.1023\/a:1006490000659 (2001).","journal-title":"Breast Cancer Res. Treat."},{"key":"19423_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1158\/1940-6207.CAPR-13-0181","volume":"7","author":"P Zhu","year":"2014","unstructured":"Zhu, P. et al. Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models. Cancer Prev. Res. (Phila). 7, 199\u2013210. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-13-0181 (2014).","journal-title":"Cancer Prev. Res. (Phila)"},{"key":"19423_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4103\/1477-3163.83043","volume":"10","author":"Z Zhu","year":"2011","unstructured":"Zhu, Z., Jiang, W., Thompson, M. D., McGinley, J. N. & Thompson, H. J. Metformin as an energy restriction mimetic agent for breast cancer prevention. J. Carcinog. 10, 17. https:\/\/doi.org\/10.4103\/1477-3163.83043 (2011).","journal-title":"J. Carcinog."},{"key":"19423_CR15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1080\/0284186X.2016.1237778","volume":"56","author":"A Ehinger","year":"2017","unstructured":"Ehinger, A. et al. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013. Acta Oncol. 56, 68\u201374. https:\/\/doi.org\/10.1080\/0284186X.2016.1237778 (2017).","journal-title":"Acta Oncol."},{"key":"19423_CR16","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.5858\/arpa.2013-0435-OA","volume":"138","author":"AM Schwartz","year":"2014","unstructured":"Schwartz, A. M., Henson, D. E., Chen, D. & Rajamarthandan, S. Histologic grade remains a prognostic factor for breast cancer regardless of the number of positive lymph nodes and tumor size: a study of 161 708 cases of breast cancer from the SEER program. Arch. Pathol. Lab. Med. 138, 1048\u20131052. https:\/\/doi.org\/10.5858\/arpa.2013-0435-OA (2014).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"19423_CR17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/bcr2607","volume":"12","author":"EA Rakha","year":"2010","unstructured":"Rakha, E. A. et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 12, 207. https:\/\/doi.org\/10.1186\/bcr2607 (2010).","journal-title":"Breast Cancer Res."},{"key":"19423_CR18","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10549-021-06229-0","volume":"187","author":"A Bhardwaj","year":"2021","unstructured":"Bhardwaj, A., Embury, M. D., Rojo, R. D., Albarracin, C. & Bedrosian, I. Efficacy of Fluvastatin and aspirin for prevention of hormonally insensitive breast cancer. Breast Cancer Res. Treat. 187, 363\u2013374. https:\/\/doi.org\/10.1007\/s10549-021-06229-0 (2021).","journal-title":"Breast Cancer Res. Treat."},{"key":"19423_CR19","doi-asserted-by":"publisher","unstructured":"Hitesh, B. M. The search for surrogacy in patient derived xenograft mouse trials: glass is less than half full. bioRxiv. https:\/\/doi.org\/10.1101\/2020.12.03.409730 (2020).","DOI":"10.1101\/2020.12.03.409730"},{"key":"19423_CR20","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12885-022-09353-2","volume":"22","author":"A Bhardwaj","year":"2022","unstructured":"Bhardwaj, A., Embury, M. D., Ju, Z., Wang, J. & Bedrosian, I. Gene signature associated with resistance to Fluvastatin chemoprevention for breast cancer. BMC Cancer. 22, 282. https:\/\/doi.org\/10.1186\/s12885-022-09353-2 (2022).","journal-title":"BMC Cancer"},{"key":"19423_CR21","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/sj.onc.1203280","volume":"19","author":"JE Green","year":"2000","unstructured":"Green, J. E. et al. The C3(1)\/SV40 T-antigen Transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene 19, 1020\u20131027. https:\/\/doi.org\/10.1038\/sj.onc.1203280 (2000).","journal-title":"Oncogene"},{"key":"19423_CR22","first-page":"313","volume":"148","author":"PJ Dawson","year":"1996","unstructured":"Dawson, P. J., Wolman, S. R., Tait, L., Heppner, G. H. & Miller, F. R. MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am. J. Pathol. 148, 313\u2013319 (1996).","journal-title":"Am. J. Pathol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19423-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19423-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19423-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:42:06Z","timestamp":1762882926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-19423-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["19423"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-19423-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"13 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors have no conflict of interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All the animal experiments and other procedures were conducted as per the guidelines of as per UTMD Anderson Cancer center\u2019s institutional animal care and use committee (IACUC) and other relevant committees such as Environment health and safety. Animals were humanely euthanized by pressure regulated CO2 inhalation followed by opening of the thoracic cavity as a secondary method to ensure death as per IACUC endorsed procedure. The study was carried out and is reported in compliance with the ARRIVE guidelines (\n                      \n                      ).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"39402"}}